Iceland· IS-EU/1/19/1354/002
Vizimpro
A dacomitinib product containing dacomitinibum inn mónóhýdrat, registered in Iceland by Pfizer Europe MA EEIG*. The same ATC class is registered in 11 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Dacomitinib is registered in 11 of 19 countries.
Countries holding a registration under ATC L01EB07 (dacomitinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Dacomitinib · ATC L01EB07
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Dacomitinibum INN mónóhýdrat
- Manufacturer
- Pfizer Europe MA EEIG*
- Country
- Iceland (IS)
- ATC code
- L01EB07
- ATC class
- Dacomitinib
- Defined daily dose
- 45 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
99 interactions on record for dacomitinib.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dacomitinib · interactions on record
99 records
- 21 severe
- 75 moderate
- 3 minor
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dacomitinib in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesVizimproPfizer Laboratories Div Pfizer Inc
- CzechiaVIZIMPROPfizer Europe MA EEIG, Bruxelles
- SpainVIZIMPRO 30 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPfizer Europe Ma Eeig
- FinlandVizimproPfizer Europe MA EEIG
- IrelandVizimpro 30 mg Film-coated tabletPfizer Europe MA EEIG
- BelgiumVizimpro 30 mgPfizer Europe MA
- NorwayVizimproPfizer Europe MA EEIG
- PolandVizimproPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Vizimpro
- Norway · Vizimpro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/35d2d206-d50f-4443-8ee8-7171ce089c2d GET /v1/drugs/35d2d206-d50f-4443-8ee8-7171ce089c2d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01EB07",
"marketed": false,
"strength": "30 mg",
"ma_number": "EU/1/19/1354/002",
"substance": "Dacomitinibum INN mónóhýdrat",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í lungnalækningum og krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43557"
}See everything about dacomitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.